On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients

International Journal of Laboratory Hematology

Volumn 34, Issue 1, 2012, Pages 35-40

  Mikovic, D ^a   Woodhams, B J ^b   Holmstrom M ^c   Elezovic, I ^d   Antovic, A ^e   Mobarrez, F ^e   Elfvinge, P ^c   Antovic, J P ^c  

^a Blood Transfusion Institute of Serbia   (Serbia)

^b Research and Development   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

FVIII; Haemophilia A; On demand treatment; Prophylactic treatment; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FIBRINOLYSIS; HEMOPHILIA A; HUMAN; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS;

ADOLESCENT; ADULT; AGED; CARBOXYPEPTIDASE U; CHILD; ENZYME ACTIVATION; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84155186674     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2011.01349.x     Document Type: Article

References (19)

1. Antovic J & Antovic A. (2003) Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay Thrombosis Haemostasis 90, 620-7.
2. Antovic J, Schulman S, Eelde A & Blomback M. (2001) Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and Pro-TAFI in patients with haemophilia. Haemophilia 7, 557-60.
3. Antovic J, Schulman S, An S, Greenfield R & Blomback M. (2004) Does an enzyme other than thrombin contribute to unexpected changes in the level of the different forms of thrombin activatable fibrinolysis inhibitor in patients with haemophilia A, haemophilia B and von Willebrand disease? Scandinavian Journal of Laboratory and Clinical Investigation 64, 745-52.
4. Bajzar L, Morser J & Neisheim M. (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. Journal of Biological Chemistry 271, 16603-8.
5. Broze G & Higuchi D. (1996) Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from haemophilia plasma. Blood 88, 3815-23.
6. Cost H, Grimaux M, Grosley M & Woodhams B. (2004) A new TAFI antigen assay independent of polymorphism 325Thr/Ile and 147Ala/Thr. In: International Proceedings: 18th International Congress on Thrombosis (eds M. Stegnar, M. Bozic, M. Kozak & P. Peternel ), 91-95 (Medimond S.r.l.). ISBN 88-7587-057-8.
7. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet J, Hemker C & Negrier C. (2005) Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thrombosis and Haemostasis 93, 475-80.
8. Foley J & Nesheim M. (2009) Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor. Journal of Thrombosis Haemostasis 7, 453-9.
9. Goldenberg N, Hathaway W, Jacobson L, McFarland K & Manco-Johnson M. (2006) Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. Haemophilia 12, 605-14.
10. Guo X, Okada N & Okada H. (2000) CRP Total (TAFI and activated TAFI) levels in plasma/serum of haemophiliacs. Microbiology and Immunology 33, 77-8.
11. He S, Blomback M, Jacobsson Ekman G & Hedner U. (2003) The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. Journal of Thrombosis Haemostasis 1, 1215-1219.
12. Lewis S, Stephens E, Florou G, Macartney N, Hathaway L & Knipping J. (2007) Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. British Journal of Haematology 138, 775-82.
13. Lisman T, Mosnier L, Lambert T, Mauser-Bunschoten E & Meijers J. (2002) Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood 99, 175-9.
14. Marx P, Dawson P, Bouma B & Meijers J. (2002) Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 41, 6688-96.
15. Mosnier L, Lisman T, Von Der Berg H, Nieuwenhuis H, Meijers J & Bouma B. (2001) The defective down regulation of fibrinolysis in Haemophilia A can be restored by increasing the TAFI plasma concentration. Thrombosis Haemostasis 86, 1035-9.
16. Sakharov D, Plow E & Rijken D. (1997) On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. Journal of Biological Chemistry 272, 14477-82.
17. Tregouet D, Schnabel R, Alessi M, Godefroy T, Declerck P, Nicaud V, Munzel T, Bickel C, Rupprecht H, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L & Morange P. (2008) Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis Haemostasis 7, 49-57.
18. Van Veen J, Gatt A, Bowyer A, Cooper P, Kitchen S & Makris M (2009) Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thrombosis Research 123, 895-901.
19. Von dem Borne P, Meijers J & Bouma B. (1995) Feedback activation of factor XI by thrombin in plasma results in additional format of thrombin that protects fibrin clots from fibrinolysis. Blood 86, 3035-42.